E-drug: New leadership in WHO (10)
----------------------------------------------------------
Regarding the recent series of postings on the appointment of Dr. Michael
Scholtz: rather than engaging in 'ad hominem' arguments it might be more
productive to approach the issue in another manner.
Before establishing criteria for performance, it would be useful to examine
those areas now under MS's responsibility where previous WHO policies and
programs have met with success, those which have not, and the reasons for
each outcome. Realistic expectations could then be established. Perhaps
E-Druggers may wish to comment ? It may also be helpful to re-examine what
each constituency now expects from WHO in the short and medium term.
Hopefully, there are common grounds for agreement, but it could be that the
composition of this forum makes no such agreement possible. Are there any
rational, constructive comments out there ?
Sincerely,
George Oswald
Medical Industry Specialist
U.S. Agency for International Development
Moscow
tel. (7095) 956-4281
e-mail: goswald@usaid.gov
The views expressed in this communication are solely those of the writer in
his private capacity, and do not represent the views of the U.S. Agency for
International Development, or any other entity of the United States
Government.
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.